25/04/2017 17:00:02

Schweiter Technologies: Annual General Meeting 2017 - Shareholders approve all proposals put forward by the Board of Directors

Related content
13 Apr - 
Schweiter Technologies: Annual General Meeting 2018 - S..
09 Mar - 
Schweiter Technologies: Figures for 2017
07 Feb - 
Schweiter Technologies: Publication Annual Results 2017

Schweiter Technologies /

Schweiter Technologies: Annual General Meeting 2017 - Shareholders approve all

proposals put forward by the Board of Directors

. Processed and transmitted by Nasdaq Corporate Solutions.

The issuer is solely responsible for the content of this announcement.

Horgen, April 25, 2017 - At the Annual General Meeting of Schweiter Technologies AG held today in Horgen, shareholders approved all proposals of the Board of Directors.

In particular, the distribution of a CHF 40 dividend per bearer share was approved. Dividends will be paid out on May 3, 2017.

Beat Siegrist, Lukas Braunschweiler, Vanessa Frey, Jan Jenisch and Jacques Sanche were all re-elected as members of the Board of Directors, and Beat Siegrist was additionally confirmed as Chairman. Jacques Sanche, Vanessa Frey and Jan Jenisch were also elected to the Compensation Committee. In the constitutive meeting following the Annual General Meeting, Jacques Sanche was elected Chairman of the Compensation Committee.

The shareholders approved the maximum total remuneration payable to the Board of Directors for their term of office up to the 2018 General Meeting and the maximum total remuneration payable to Management for financial year 2018.

Operational business has been developing gratifying since the start of the year and is in line with the forecast communicated in the media release dated March 13, 2017.

For further information please contact:

Martin Klöti, CFO

Tel. +41 44 718 33 03, fax +41 44 718 34 51, martin.kloeti@schweiter.com

Schweiter Technologies AG, Neugasse 10, CH - 8810 Horgen, Switzerland

Tel. +41 44 718 33 03 Fax +41 44 718 34 51 info@schweiter.com

www.schweiter.com

Please find the Media release in the PDF attached:

Media release (PDF)


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Schweiter Technologies via Globenewswire

--- End of Message ---

Schweiter Technologies

Neugasse 10 Horgen Switzerland

ISIN: CH0010754924;

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Due to Popular Demand
2
Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care
3
Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
4
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)
5
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)

Related stock quotes

Schweiter I 1,058.00 0.8% Stock price increasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 June 2018 04:23:26
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180619.1 - EUROWEB7 - 2018-06-24 05:23:26 - 2018-06-24 04:23:26 - 1000 - Website: OKAY